Cancer of Stomach — Audit of the Spanish EURECCA Esophagogastric Cancer Registry
Citation(s)
Allum W, Osorio J EURECCA oesophago-gastric cancer project. Cir Esp. 2016 May;94(5):255-6. doi: 10.1016/j.ciresp.2015.12.005. Epub 2016 Mar 2. English, Spanish.
Bray F, Parkin DM Evaluation of data quality in the cancer registry: principles and methods. Part I: comparability, validity and timeliness. Eur J Cancer. 2009 Mar;45(5):747-55. doi: 10.1016/j.ejca.2008.11.032. Epub 2008 Dec 29. Review.
Kjaer DW, Larsson H, Svendsen LB, Jensen LS Changes in treatment and outcome of oesophageal cancer in Denmark between 2004 and 2013. Br J Surg. 2017 Sep;104(10):1338-1345. doi: 10.1002/bjs.10586. Epub 2017 Jul 18.
Parkin DM, Bray F Evaluation of data quality in the cancer registry: principles and methods Part II. Completeness. Eur J Cancer. 2009 Mar;45(5):756-64. doi: 10.1016/j.ejca.2008.11.033. Epub 2009 Jan 6. Review.
Sakkestad ST, Olsen BC, Karliczek A, Dahl O, Pfeffer F Validity of Norwegian Rectal Cancer Registry data at a major university hospital 1997-2005. Acta Oncol. 2015 Nov;54(10):1723-8. doi: 10.3109/0284186X.2015.1031913. Epub 2015 Apr 23.
Wouters MW, Jansen-Landheer ML, van de Velde CJ The Quality of Cancer Care initiative in the Netherlands. Eur J Surg Oncol. 2010 Sep;36 Suppl 1:S3-S13. doi: 10.1016/j.ejso.2010.06.004. Epub 2010 Jun 23.
Validation of the Data Quality and Early Outcomes of the Spanish EURECCA Esophagogastric Cancer Registry
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
